Floris ten Have

Floris ten Have

With his expertise in all areas of EU and Dutch competition law, Floris advises multinational companies active in numerous industries and has extensive experience, for example, in the pharmaceutical and financial sectors.

His practice covers the full range of topics within the antitrust area, including merger control, cartel investigations and litigation, abuse of dominance and state aid cases.

In 2014 Floris completed a secondment at Quinn Emanuel Urquhart & Sullivan, LLP in New York where he gained experience with regard to US antitrust litigation.

Floris has a Master of Law from University of Amsterdam and regularly teaches competition law.

  • Languages: Dutch, English
  • Admitted to the Amsterdam Bar: 2007
  • Partner since: 2019

Experience

Related news

21.03.2019 EU law
Ignace Vernimme, Floris ten Have and Manuel Campolini are speakers during the Legal Affairs Conference.

Speaking slot - Ignace Vernimme, IP Partner at Stibbe Brussels, moderates a roundtable discussion on 'second medical use patents'. Manuel Campolini, of-counsel at Stibbe Brussels, co-moderates this session. Floris ten Have, Competition and Regulation Partner at Stibbe Amsterdam, chairs a session on opportunities and challenges for biosimilar medicine developers.

Read more

21.03.2019 NL law
15 aspects of Brexit you did not know

Short Reads - A Brexit without a deal, or with a deal that does not cover all relevant aspects, is still a potential scenario. We have highlighted a number of unexpected legal consequences of Brexit in such a no deal or incomplete deal scenario.

Read more

07.02.2019 NL law
The ACM follows EU approach in its first pharmaceutical merger

Short Reads - The Dutch Authority for Consumers and Markets (ACM) recently reviewed its first merger between two pharmaceutical companies. In its conditional clearance of Aurobindo's acquisition of certain European Apotex assets, the ACM followed the European Commission's approach in assessing the merger's impact on competition. Companies will welcome the news that pharma mergers will be reviewed in a similar fashion, irrespective of whether the ACM or the European Commission conducts the review.

Read more

Other specialists

Our website uses functional cookies for the functioning of the website and analytic cookies that enable us to generate aggregated visitor data. We also use other cookies, such as third party tracking cookies - please indicate whether you agree to the use of these other cookies:

Privacy – en cookieverklaring